Acrivon therapeutics reports first quarter 2024 financial results and business highlights

Watertown, mass., may 14, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics (ap3), today reported financial results for the first quarter ended march 31, 2024 and reviewed business highlights.
ACRV Ratings Summary
ACRV Quant Ranking